Matrix metalloproteinase-12 by M2 macrophages induced epithelial to mesenchymal transition in chronic rhinosinusitis

Joo-Hoo Park1,2,3, Jae-Min Shin1,2,4, Hyun-Woo Yang1,2,3

  • 1Upper Airway Chronic Inflammatory Diseases Laboratory, Korea University College of Medicine, Seoul, Republic of Korea.

Plos One
|December 31, 2024
PubMed

Insights

Matrix metalloproteinase-12 (MMP-12) from M2 macrophages drives epithelial-mesenchymal transition (EMT) in nasal cells, contributing to chronic rhinosinusitis with nasal polyps (CRSwNP). Inhibiting MMP-12 may offer therapeutic potential for CRSwNP.

Area of Science:

  • Immunology
  • Cell Biology
  • Pathophysiology

Background:

  • Th2 inflammation and epithelial-mesenchymal transition (EMT) are key in chronic rhinosinusitis with nasal polyps (CRSwNP).
  • M2 macrophages and matrix metalloproteinase-12 (MMP-12) are implicated in CRSwNP pathogenesis.

Purpose of the Study:

  • To investigate if MMP-12, produced by M2 macrophages, induces EMT in nasal epithelial cells.
  • To explore the role of MMP-12 in CRSwNP airway inflammation and remodeling.

Main Methods:

  • Quantitative RT-PCR, Western blotting, and immunofluorescence staining were used.
  • Expression of MMP-12, EMT markers (E-cadherin, vimentin, α-SMA, fibronectin) were analyzed.
  • Co-culture systems and an MMP-12 inhibitor (MMP408) were employed.

Main Results:

  • MMP-12 expression was elevated in CRSwNP tissues and M2-like THP-1 cells.
  • MMP-12 induced EMT in primary nasal epithelial cells and air-liquid interface cultures.
  • MMP-12 inhibition reversed EMT-related factor changes.

Conclusions:

  • MMP-12 from M2 macrophages promotes EMT in nasal epithelial cells.
  • MMP-12 is a potential therapeutic target for CRSwNP pathogenesis.